These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 22453333)

  • 1. The Prostate cancer Research International: Active Surveillance study.
    Bangma CH; Bul M; Roobol M
    Curr Opin Urol; 2012 May; 22(3):216-21. PubMed ID: 22453333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MRI and surveillance.
    Ouzzane A; Puech P; Villers A
    Curr Opin Urol; 2012 May; 22(3):231-6. PubMed ID: 22388665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Active surveillance: the Canadian experience.
    Klotz L
    Curr Opin Urol; 2012 May; 22(3):222-30. PubMed ID: 22453335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychological aspects of active surveillance.
    van den Bergh RC; Korfage IJ; Bangma CH
    Curr Opin Urol; 2012 May; 22(3):237-42. PubMed ID: 22357407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic analysis of active surveillance for localized prostate cancer.
    Kim S; Dall'Era MA; Evans CP
    Curr Opin Urol; 2012 May; 22(3):247-53. PubMed ID: 22388666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of 5-alpha-reductase inhibitors in active surveillance.
    Margel D; Fleshner N
    Curr Opin Urol; 2012 May; 22(3):243-6. PubMed ID: 22472511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer overdiagnosis and overtreatment.
    Klotz L
    Curr Opin Urol; 2012 May; 22(3):203-9. PubMed ID: 22472510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indications for intervention during active surveillance of prostate cancer: a comparison of the Johns Hopkins and Prostate Cancer Research International Active Surveillance (PRIAS) protocols.
    Kates M; Tosoian JJ; Trock BJ; Feng Z; Carter HB; Partin AW
    BJU Int; 2015 Feb; 115(2):216-22. PubMed ID: 24904995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Active surveillance: oncologic outcome.
    Venderbos LD; Bokhorst LP; Bangma CH; Roobol MJ
    Curr Opin Urol; 2013 May; 23(3):268-72. PubMed ID: 23425994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Follow-up in Active Surveillance for Prostate Cancer: Strict Protocol Adherence Remains Important for PRIAS-ineligible Patients.
    Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
    Eur Urol Oncol; 2019 Sep; 2(5):483-489. PubMed ID: 31411970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The economics of active surveillance for prostate cancer.
    Dall'Era MA
    Curr Opin Urol; 2013 May; 23(3):278-82. PubMed ID: 23449496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Active surveillance with selective delayed intervention for favorable risk prostate cancer.
    Klotz L
    Urol Oncol; 2006; 24(1):46-50. PubMed ID: 16414494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.
    Auprich M; Bjartell A; Chun FK; de la Taille A; Freedland SJ; Haese A; Schalken J; Stenzl A; Tombal B; van der Poel H
    Eur Urol; 2011 Nov; 60(5):1045-54. PubMed ID: 21871709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: Active Surveillance' study.
    van den Bergh RC; Vasarainen H; van der Poel HG; Vis-Maters JJ; Rietbergen JB; Pickles T; Cornel EB; Valdagni R; Jaspars JJ; van der Hoeven J; Staerman F; Oomens EH; Rannikko A; Roemeling S; Steyerberg EW; Roobol MJ; Schröder FH; Bangma CH
    BJU Int; 2010 Apr; 105(7):956-62. PubMed ID: 19817747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Further support for active surveillance in the management of low-volume, low-grade prostate cancer.
    Albertsen P
    Eur Urol; 2010 Dec; 58(6):836-7. PubMed ID: 20851512
    [No Abstract]   [Full Text] [Related]  

  • 16. Active surveillance for prostate cancer: a review.
    Klotz L
    Arch Esp Urol; 2011 Oct; 64(8):806-14. PubMed ID: 22052761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer.
    Aizer AA; Paly JJ; Zietman AL; Nguyen PL; Beard CJ; Rao SK; Kaplan ID; Niemierko A; Hirsch MS; Wu CL; Olumi AF; Michaelson MD; D'Amico AV; Efstathiou JA
    J Clin Oncol; 2012 Sep; 30(25):3071-6. PubMed ID: 22851571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
    Zhu X; van Leeuwen PJ; Bul M; Otto SJ; de Koning HJ; Bangma CH; Schröder FH; Roobol MJ
    Eur Urol; 2011 Aug; 60(2):330-6. PubMed ID: 21601352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment.
    Soloway MS; Soloway CT; Eldefrawy A; Acosta K; Kava B; Manoharan M
    Eur Urol; 2010 Dec; 58(6):831-5. PubMed ID: 20800964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acceptance and durability of surveillance as a management choice in men with screen-detected, low-risk prostate cancer: improved outcomes with stringent enrollment criteria.
    Miocinovic R; Jones JS; Pujara AC; Klein EA; Stephenson AJ
    Urology; 2011 Apr; 77(4):980-4. PubMed ID: 21256549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.